View Post

Celgene’s CC-486 positioned to become standard maintenance therapy in acute myeloid leukemia

In Clinical Studies News by Barbara Jacoby

Source: Global Data From: Celgene plans to pursue a new drug application (NDA) in Q1 2020 for its formulation of oral azacitidine (CC-486) after data from the Phase III QUAZAR AML-001 trial showed that maintenance therapy can prolong the overall survival (OS) of acure myeloid leukemia (AML) patients compared with placebo. As such, CC-486 is set to address a …

View Post

Drug Companies to Try a Unified Front Against Cancer

In In The News by Barbara Jacoby

By: ANDREW POLLACK From: Some leading pharmaceutical companies are joining forces in an effort to speed the testing of new types of cancer drugs that harness the body’s immune system to battle tumors. The cooperative effort, announced on Monday, will include Amgen, Celgene and some smaller companies. The effort, known as the National Immunotherapy Coalition, will try to rapidly …